Emugrobart

Highest phase reached
Phase 2
www.ebi.ac.uk
Drug type
Antibody
www.ebi.ac.uk

Listing at source
Listed
Highest phase reached
Phase 2
www.ebi.ac.uk

Drug type
Antibody
www.ebi.ac.uk
Drug name
Emugrobart
www.ebi.ac.uk

  • emugrobart
  • Emugrobart
  • emugrobart [INN]
  • emugrobart inn
  • gym329
  • Gym329
  • GYM329
  • h gamma1 heavy chain humanized 1 447 vh homo sapiens ighv3 66 01 69 1 ighd ighj1 01 100 cdr imgt 8 7 13 26 33 51 57 96 108 1 119 homo sapiens ighg1 03v g1m3 g1m17 ng1m1 ch1 k120 ch2 e12 m14 g1v86 ch2 y1 3 d2 i26 k115 g1v87 v14 p90 g1v88 ch2 r94 ch3 r1 2 g1v89 ch3 t116 r118 g1v78 1 ch3 l107 a114 t116 ch1 r120 k 216 120 217 hinge 1 15 218 232 ch2 l1 3 y 236 p2 d 240 t14 v 252 v26 i 266 t90 p 309 q94 r 313 a115 k 332 233 342 ch3 e12 358 m14 360 p1 2 r 345 m107 l 430 n114 a 436 y116 t 438 q118 r 440 s120 e 442 343 447 chs g1 del k2 del 120 447 222 217 disulfide with l kappa light chain humanized 1 217 vkappa homo sapiens igkv3d 7 01 77 7 igkj2 02 90 0 l124 v 107 cdr imgt 8 3 10 27 34 52 54 91 100 1 110 homo sapiens igkc 01 100 km3 a45 1 v101 c kappa a45 1 156 v101 194 111 217 dimer 228 228 231 231 bisdisulfide produced in chinese hamster ovary cho cells cell line cho dxb11 glycoform alfa
  • H-gamma1 heavy chain humanized (1-447) [VH (Homo sapiens IGHV3-66*01 (69.1%) -(IGHD) -IGHJ1*01 (100%), CDR-IMGT [8.7.13] (26-33.51-57.96-108)) (1-119) -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1 CH1 K120, CH2 E12, M14, G1v86 CH2 Y1.3, D2, I26, K115, G1v87 V14, P90, G1v88 CH2 R94, CH3 R1.2, G1v89 CH3 T116, R118, G1v78-1 CH3 L107, A114, T116 (CH1 R120>K (216) (120-217), hinge 1-15 (218-232), CH2 L1.3>Y (236), P2>D (240), T14>V (252), V26>I (266), T90>P (309), Q94>R (313), A115>K (332) (233-342), CH3 E12 (358), M14 (360), P1.2>R (345), M107>L (430), N114>A (436), Y116>T (438), Q118>R (440), S120>E (442) (343-447), CHS G1>del, K2>del) (120-447)], (222-217')-disulfide with L-kappa light chain humanized (1'-217') [VKAPPA (Homo sapiens IGKV3D-7*01 (77.7%) -IGKJ2*02 (90.0%) L124>V (107'), CDR-IMGT [8.3.10] (27'-34'.52'-54'.91'-100')) (1'-110') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (C-KAPPA A45.1 (156'), V101 (194')) (111'-217')]; dimer (228-228'':231-231'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-DXB11, glycoform alfa
  • Immunoglobulin G1 [236-tyrosine,240-aspartic acid,252-valine,266-isoleucine,309-proline,313-arginine,332-lysine,345-arginine,430-leucine,436-alanine,438-threonine,440-arginine,442-glutamic acid,de-448-glycine,de-449-lysine], anti-(human latent growth differentiation factor 8) (human-Oryctolagus cuniculus monoclonal RO7204239 γ1-chain), disulfide with human-Oryctolagus cuniculus monoclonal RO7204239 κ-chain, dimer
  • immunoglobulin g1 236 tyrosine 240 aspartic acid 252 valine 266 isoleucine 309 proline 313 arginine 332 lysine 345 arginine 430 leucine 436 alanine 438 threonine 440 arginine 442 glutamic acid de 448 glycine de 449 lysine anti human latent growth differentiation factor 8 human oryctolagus cuniculus monoclonal ro7204239 γ1 chain disulfide with human oryctolagus cuniculus monoclonal ro7204239 κ chain dimer
  • immunoglobulin g1 kappa anti homo sapiens mstn myostatin growth differentiation factor 8 gdf8 gdf 8 latent myostatin complex humanized monoclonal antibody
  • immunoglobulin G1-kappa, anti-[Homo sapiens MSTN (myostatin, growth differentiation factor 8, GDF8, GDF-8) latent myostatin complex], humanized monoclonal antibody;
  • rg 6237
  • rg 70240
  • RG-6237
  • RG-70240
  • ro 7204239
  • RO-7204239
  • ro7204239
  • Ro7204239
  • RO7204239

CAS registry numbers
  • 2922218-19-5
ChEMBL ID
CHEMBL6068245
www.ebi.ac.uk
FDA ingredient codes (UNII)
  • INA01972XV

First in class
No
Orphan designation
No

Drug name stem
-bart

  • Condition
    Muscular Atrophy, Spinal
    Highest recorded phase
    2
    Condition identifier
    EFO:0008525
    Subject identifier
    D009134
  • Condition
    Muscular Dystrophy, Facioscapulohumeral
    Highest recorded phase
    2
    Condition identifier
    Orphanet:269
    Subject identifier
    D020391

  • Condition identifier
    EFO_0008525
  • Condition identifier
    HP_0001513
    Highest recorded phase
    2
  • Condition identifier
    HP_0025502
    Highest recorded phase
    2
  • Condition identifier
    MONDO_0001347
    Highest recorded phase
    2
  • Condition identifier
    MONDO_0001516
    Highest recorded phase
    2
  • Condition identifier
    MONDO_0005148
    Highest recorded phase
    1

Prodrug
No
Chirality
Single enantiomer
Inorganic
No
Natural product
No

  • Component
    Heavy chain
    Type
    Protein
    Sequence
    QVQLVESGGGLVQPGGSLRLSCAVSGIDLSHDDISWVRQAPGKGLEWVSIISYAGSTYYASWAKGRLTISKDTSKNQVVLTMTNMDPVDTATYYCARGVPAYSHGGDLWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEYLGGDSVFLFPPKPKDVLMISRTPEVTCVVIDVSHEDPEVKENWYVDGVEVHNAKTKPREEQYNSTYRVVSVLPVLHRDWLNGKEYKCKVSNKALPKPIEKTISKAKGQRREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHAHTTRKELSLSP
  • Component
    Disulfide bridges
    Sequence
    22-95 $ 22''-95'' $ 23'-90' $ 23'''-90''' $ 137'-197' $ 137'''-197''' $ 146-202 $ 146''-202'' $ 222-217' $ 222''-217''' $ 228-228'' $ 231-231'' $ 263-323 $ 263''-323'' $ 369-427 $ 369''-427''
  • Component
    Light chain
    Type
    Protein
    Sequence
    DIVMTQSPATLSLSPGERATLSCTTSQSVYHENWLSWFQQKPGQPPKLLIYWASTLAYGVPSRFSGSGSGTDFTLTISSLQPEDAATYYCAGGYGGGRYAFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
  • Component
    Glycosylation sites (N)
    Sequence
    1 $ 1'

Related records

Trials (5)

In development for (2)